Fluorine substituted 1,2,4-triazinones have been synthesized via alkylation, amination, and/or oxidation of 6-(2-amino-5-fluorophenyl)-3-thioxo-3,4-dihydro-1,2,4-triazin-5(2H)-one 1 and 4-fluoro-N-(4-fluoro-2-(5-oxo-3-thioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)phenyl)benzamide 5 as possible anti-HIV-1 and CDK2 inhibitors. Alkylation on positions 2 and 4 in 1,2,4-triazinone gave compounds 6-8. 
Introduction
Human immunodeficiency virus (HIV) type-1 is the causative agent of acquired immunodeficiency syndrome (AIDS), which is one of the serious global health problems [1] . The currently approved anti-HIV drugs can be divided into five groups: reverse transcriptase inhibitors (RTIs), protease inhibitors [2] (PIs), fusion inhibitors (FIs), coreceptor inhibitors (CRIs), and integrase inhibitors (INIs). This arsenal of drugs, which is used in combinations, has moved the prognosis of HIV patients from that of high morbidity and mortality to, for many at least, a chronic, manageable but still complex disease [3] [4] [5] . However, the use of these drugs has been relatively limited by their toxicity [6] , drug resistance development [7] , and, more worryingly, the fact that some newly HIV-infected patients carry viruses that are already resistant to the currently approved AIDS treatments [8] . These issues along with drug-related side effects make it apparent that new anti-HIV drugs with novel mechanisms of action are clearly needed.
On the other hand, during the past 30 years, a variety of approaches have been taken for cancer chemotherapy and many antitumor drugs have been developed for clinical use. In the treatment of solid tumors, however, the conventional approaches have met with only limited success and cancer still remains as one of the leading causes of human mortality [9] .
Chemotherapy drugs are sometimes feared because of a patients' concern about its toxic effects. There are three goals associated with the use of the most commonly used anticancer agents: (a) damage the DNA of the affected cancer cells, (b) inhibit the synthesis of new DNA strands to stop the cells from replicating, and (c) stop the mitosis or the actual splitting of the original cell into two new daughter cell [10] .
In the past few years fluorine substituted heterocyclic nitrogen systems have been incorporated into drug discovery research [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] to improve the physicochemical properties of drugs. Organic fluorine is a prominent tool in the design and improvement of pharmacokinetic properties of drug molecules. Replacing hydrogen and other functional groups with fluorine can have a dramatic effect on the modulation of electronic, lipophilic, and steric parameters, all of which can critically influence both the pharmacodynamic and pharmacokinetic properties of drugs. Substitution of fluorine into a potential drug molecule not only alters the electronic environment, but it also influences the properties of neighboring functional groups. Fluorine can have significant effects on the binding affinity in protein-ligand complexes. The DNA polymerase inhibitors fludarabine (I) (F-ara-A), Figure 1 clofarabine (II), and tezacitabine (III) are used as cancer chemotherapeutic agents [24] , while Gleevec (IV) is used as catalytic inhibitor of imatinib mesylate [25] . In addition, BX-1382BS (V) showed a significant activity as protein kinase inhibitor [26] and a cyanopyrimidine scaffold JNJ-17029259 (VI) is an oral inhibitor of VEGF-mediated signal transduction [27] (Figure 1) . Recently a great deal of synthetic efforts has been spent on fluorinated uncondensed 1,2,4-triazines by our group searching for new anti-HIV and anticancer agents [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] (compounds A-F; Figure 2 ).
Fluorine incorporation on key positions plays a significant role to alter the physicochemical and biological characteristics of organic compounds. Frequently, it is found that a fluorine substituent leads to an enhancement of the binding affinity of a molecule with proteins through a noncovalent bond formation. Fluorine increases binding affinity, reduces plasma protein binding leading to a higher free fraction of the drug, and increases cell penetration. The combination of these effects results in a dramatically improved biological activity. Based on these valuable observations and in part of our continuing efforts in drug development, the present work describes an attempt towards the synthesis of fluorine substituted 1,2,4-triazinones. The purpose of the work is to extend the scope of our previous studies [29, 30] and to substitute fluorine on various positions in 1,2,4-triazines in order to obtain effective anti HIV-1 and CDK2 inhibiting agents.
Experimental
2.1. Chemistry. Melting points were determined on an electrothermal Bibby Stuart Scientific melting point apparatus and are uncorrected. The infrared (IR) spectra were recorded on PerkinElmer RXI FT-IR infrared spectrophotometer using the KBr pellet technique. Electronic absorption spectra were recorded in DMF on Shimadzu UV-Visible 3101 PC spectrophotometer.
1 H and 13 C NMR spectra were recorded on a Bruker DPX-400 FT NMR spectrometer using tetramethylsilane as the internal standard DMSO-6 as a solvent (chemical shifts in , ppm).
19 F NMR spectra were determined at 84.25 MHz using hexafluorobenzene as an internal standard. Splitting patterns were designated as follows: s: singlet; m: multiplet. Mass spectra were measured on a GCMS-Q 1000 Ex spectrometer. Elemental analyses were performed on a 2400 PerkinElmer Series 2 analyzer. Follow-up of the reactions and checking the homogeneity of the compounds were made by TLC on silica gel-protected aluminum sheets (Type 60 F254, Merck) and the spots were detected by exposure to UV-lamp at 254.
The anti-HIV and anticancer activity were evaluated in DTP, DCT, National Cancer Institute, Bethesda, MD 20892, USA.
6-(2-Amino-5-fluorophenyl)-3-thioxo-3,4-dihydro-1,2,4-triazin-5(2H)-one (1).
A mixture of 5-fluoroisatin (0.001 mol in warm 5% aqueous NaOH) and thiosemicarbazide (0.001 mol, in hot water 10 mL) was refluxed for 2 h. The reaction mixture was then poured onto ice and neutralized with dil. HCl. (2) . A mixture of 1 (0.001 mol) and monochloroacetic acid (0.002 mol) in ethanolic NaOH (5%, 50 mL) was warmed for 30 min and then cooled and poured onto ice-cold dil. acetic acid. The product is precipitated as pale solid which was then filtered and crystallized from acetic acid to give yellow crystals of compound 2. Yield 70%, m.p. 262-264 ∘ C. 
2-((6-(2-((
Carboxymethyl)amino)-5-fluorophenyl)-5- oxo-4,5-dihydro-1,2,4-triazin-3-yl)thio)acetic acid
4-Fluoro-N-(4-fluoro-2-(5-oxo-3-thioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)phenyl)benzamide (5).
A mixture of compound 1 (0.001 mol) and 4-fluorobenzoyl chloride (0.001 mol) in dry pyridine (10 mL) was warmed for 10 min, cooled, and then poured on ice. 
N-(2-(2,4-Disubstituted-5-oxo-3-thioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)-4-fluorophenyl)-4-fluorobenzamide (6-8).
A mixture of 5 (0.001 mol) methanol or morpholine or 2,2 -dipyridylamine (0.001 mol) in methanol (20 mL) and formaldehyde (0.001 mol) was refluxed for 2 h. The reaction mixture was cooled to acquire room temperature and then poured onto ice-cold water. The solid product precipitated was filtered and crystallized from methanol to form yellow-orange crystals. (9) (10) (11) (12) . A mixture of 5 (0.001 mol) and sulfathiazole or sulfaoxazole or 4-fluoroaniline or 2,2 -dipyridylamine (0.001 mol) in absolute ethanol (50 mL) was refluxed for 6 h. On cooling a solid is separated which is filtered and crystallized from ethanol to give yellow crystals of 9-12. 
4-Fluoro-N-(4-fluoro-2-(3-(substituted-amino)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl)phenyl)benzamide

4-Fluoro-N-(4-fluoro-2-(3-((4-fluorophenyl)amino)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl)phenyl)benzamide (11)
Procedure A. Equimolar mixture of compound 14 and 4-fluoroaniline was refluxed for 6 h then cooled. The solid thus obtained was filtered and crystallized from ethanol to give 11 as faint yellow crystals. Yield 78%, m.p. 247-249 ∘ C.
Procedure B. An equimolar mixture of compound 5 and 4-fluoroaniline in ethanol (50 mL) was refluxed for 6 h and then cooled. The resulting solid was filtered and crystallized from ethanol to give faint yellow crystals of 11. Yield 75%, m.p. 247-249 ∘ C. (17) . A mixture of compounds 1 (0.001 mol) and 5 (0.001 mol) in DMF (50 mL) was refluxed for 1 h. The reaction mixture was left to cool at room temperature. The solid thus generated was filtered and crystallized from acetic acid to give 17 as yellow crystals. Yield 65%, m.p. 230 (18) . An equimolar mixture of 1 and 5 (0.001 mol) in isopropyl alcohol (50 mL) was refluxed for 6 h. Some of the solvent of reaction mixture was evaporated in vacuo. The product was separated as brownish orange solid which was crystallized from ethanol to form orange crystals of compound 18. 
2-((6-(5-Fluoro-2-(4-fluorobenzamido)phenyl)-5-oxo-4,5-dihydro-1,2,4-triazin-3-yl)thio)acetic acid (13
2,2,2-Tris((6-(5-fluoro-2-(4-fluorobenzamido)phenyl)-5-oxo-4,5-dihydro-1,2,4-triazin-3-yl)thio)acetic acid
4-Fluoro-N-(4-fluoro-2-(3-((4-fluoro-2-(5-oxo-3-thioxo-2,3,4,5-tetrahydro-1,2,4-triazin-6-yl)phenyl)amino)-5-oxo-4,5-dihydro-1,2,4-triazin-6-yl)phenyl)benzamide
Biological Evaluation
Anti-HIV-1 Activity.
All the new synthesized compounds have been evaluated for their in vitro anti-HIV activity that was performed on T-4 lymphocytes infected and uninfected with HIV-1 using DMSO as solvent. The assay involves the killing of T-4 lymphocytes by HIV. Uninfected cells with the compound serve as a toxicity control, and infected and uninfected cells without the compound serve as basic controls. Cultures are incubated at 37 ∘ C in a 5% carbon dioxide atmosphere for 6 days. The tetrazolium salt, XTT, is added to all wells, and cultures are incubated to allow formazan color development by viable cells. Compounds that degenerate or are rapidly metabolized in the culture conditions may not show activity in this screen. Zidovudine (AZT) at 10 M was used as a control. The viability of the cells was determined spectrophotometrically to quantitate formazan production and in addition is viewed microscopically for detection of viable cells and confirmation of protective activity. Drug-treated virus-infected cells are compared with drug treated noninfected cells and with other appropriate controls (untreated infected and untreated noninfected cells, drugcontaining wells without cells) on the same plate.
CDK2 Inhibition
Assay. CDK2-cyclin E kinase was expressed and assayed as previously described [39] . Kinase activity was expressed as a percentage of maximum activity. The concentration of the test compounds required to decrease the CDK activity by 50% was determined from dose-response curves and designated IC 50 . for NH, NH 2 and at 1661 and 1255 cm −1 for C=O and C-F functional groups, respectively. The mass spectrum showed a peak at m/z 254 (M + H 2 O, 5%) with a base peak at 103. Similarly, compound 3 exhibited in its IR spectrum three peaks at 3310, 2929, and 2862 cm −1 for NH and methyl groups. The mass of 3 exhibited a peak at m/z 284 (M + H 2 O, 5%) with a base peak at 88. The 1 H NMR spectra of 3 showed two singlets at 3.2 and 3.5 ppm for N-CH 3 and S-CH 3 protons.
Results and Discussion
El-Gendy et al. [37] , obtained 1,1-di[4 -amino-6 -substituted-5-oxo-1,2,4-triazin-3-yl)thio]acetic acid as anticancer agent. Similarly refluxing compound 1 with 1,1-dichloroacetic acid (2 : 1 by mole) in DMF produced the 1,1-di[heteroaryl]-thioacetic acid 4 through nucleophilic displacement of chlorine by thioheterocyclic moieties (Scheme 2). The UV absorption spectra of 4 recorded max at 266.5 nm while that of 1 at 282.8 nm.
Reaction of 1 with 4-fluorobenzoyl chloride in dry pyridine furnished 5 (Scheme 3). IR spectrum of 5 showed two carbonyl groups at 1663 and 1610 cm −1 . The 13 C NMR spectrum showed peaks at 173.15, 164.14, and 158.72 ppm attributed to C=S, C=O, and CONH carbons. The mass Scheme 2 spectrum exhibited a peak at m/z 360 (M + 4, 6%) with a base peak at 89. Compound 5 was used as starting material for building some more N 2 -substituted and/or C 3 -NH substituted 1,2,4-triazinones. Thus hydroxymethylation of 5 using methanolformaldehyde yielded 2,4-dihydroxymethyl derivative 6 which on its treatment with secondary amine as morpholine and/or 2,2-dipyridylamine under the same reaction conditions Mannich bases of the type 7 and/or 8 were isolated (Scheme 3). IR spectrum of 6 showed absorptions at 3537, 2935, 2890, 1498, and 1440 cm −1 mainly attributed to O-H, C-H stretching, and CH 2 bending vibrations. The 1 H NMR spectrum of 6 showed peaks at 12.54, 10.15 and 8.04 ppm for NH and OH protons. The 13 C NMR spectrum, however, exhibited three resonance signals at 164.99, 163.32, and 157 ppm for C=S, C=O, and CONH groups and at 39.0 ppm for CH 2 carbon.
3-Substituted amino-1,2,4-triazine derivatives have shown chemotherapeutic [40] activities and have been proven as copper corrosion inhibitors [41] . Thus a simple nucleophilic displacement of SH group of 1,2,4-triazines with NH of different amines and sulfa drugs via reaction of compound 5 with sulfa drugs (sulfathiazole and sulfoxazoles), 4-fluoroaniline, and 2,2-dipyridylamine gave 3-substitutedamino-6-[5 -fluoro-2 -(4 -fluorophenylcarbamidophenyl)-1,2,4-triazin-5(4H)ones 9-12 (Scheme 3). The IR spectrum of compound 11 showed absorptions at 1255 and 658 cm −1 for C-F. The 13 C NMR spectrum showed absence of C=S carbon. The mass spectra exhibited m/z 437 (M-45, 392, 1.0%) with a base peak at 148 for the fragment C 7 H 3 N 3 F.
Alkylation of 3-mercapto-1,2,4-triazinone 5 using monochloroacetic acid in dry pyridine produced the mercaptoacetic acid derivative 13. Decarboxylation of 13 by warming it with aqueous K 2 CO 3 afforded 6- which are attributed to C-F and C-S of the thioether. The 13 C NMR spectrum lacks a signal for C=S carbon. However, resonances at 132.11 ppm for C-S carbon in addition to a signal at 164.98 ppm for carbonyl carbon.
Finally synthesis of fluorine substituted 1,2,4-triazinone bearing other amino-1,2,4-triazinone 18 was done by refluxing compounds 1 and 15 in boiling isopropyl alcohol as amination reaction (Scheme 5). The IR spectrum of 18 showed bands at 3320, 3300, 1668, 1620, and 1185 cm −1 for NH, NH, C=O, CONH, and C=S groups. The mass spectrum showed a peak at m/z 368 (M-196, 7%) along with a base peak at 89 for CH 2 N 3 S.
The presence of fluorine was confirmed by 19 F NMR. A single fluorine atom attached to phenyl and/or benzoyl ring appeared in the region 120-130 ppm using hexafluorobenzene as internal standard.
The mass fragmentation patterns of some of the target molecules are mentioned in Schemes 6, 7, 8, 9 , and 10. infected with HIV using DMSO as solvent. The assay basically involves the killing of T4 lymphocytes by HIV compounds that degenerate or are rapidly metabolized in the culture conditions may not show activity in this screen. The viability of the cells was determined spectrophotometrically using the tetrazolium assay procedure. The results obtained are reported in Table 1 .
The results revealed by Table 1 suggest that compounds 5, 11, 14, 16, and 17 displayed very good anti-HIV-1 activity having a favorable selectivity index between 3 and 7. The CC 50 and EC 50 data are used to calculate the selectivity index (SI) of each compound as an estimate of a therapeutic window and a mechanism to identify candidates for efficacy studies. The other compounds though are active as anti-HIV-1 agents but do not show very good selectivity index ratio. The remaining compounds exhibited an average to poor activity with selective index <3 (Table 1) . In particular, a high activity level was observed for compounds 11 and 14. A close examination of these two compounds reveals that both the structures have 4-fluoro-N-(4-fluorophenyl)benzamide part connected at position 6 in triazinone nucleus. Similarly, in compound 16 which is an oxidised dimer of the active compound 5, the selectivity index is almost doubled. The antiviral activity diminishes if the triazinone ring experience crowding at carbon-3 in triazinone part as in case of 15 and 18. Sulfonamide moieties, however, could not contribute towards improving the antiviral profile; rather it significantly diminishes the selectivity index ratio as can be seen in compounds 9 and 10. The influence of fluorine on the acidity, hydrogen bonding, and lipophilicity of these systems can be envisaged not only a biological activity modulator but also influences the bioavailability of the drug. The active fluorine compounds obtained are capable of forming stronger DNA complexes than their nonfluorinated analogs. These results suggest that the electronic nature of the chain of 3-thioxo-1,2,4-triazines tethering an intercalator that not only influences the DNAbinding process but might also be used to tune the new DNA-drug complex. It can be implied that the fluorine substituted-3-thioxo-1,2,4-triazin-5-ones represent suitable prodrug principle leading to higher bioavailability.
The biological activity depends not only on the site of fluorination and the geometry of the conjugate carbanion 96 (2) 76 (75) 152 (4) 265 (78) 89 (100) 123 ( formed but also on the total electronegativity of new heterocyclic nitrogen systems. In view of these characteristics and the results obtained in Table 1 we can infer that fluorination invariably increases C-H acidity through a combination of inductive and hyperconjugative resonance stabilization of the carbanion and thus influences the biological activity of this series of compounds (Figure 3 ).
Anticancer Activity.
The new fluorine substituted 1,2,4-triazinones (1-18) have been evaluated to inhibit activity of CDK2 in a biochemical assay. The inhibitory concentration (IC 50 ) values were obtained according to the reported methods [39, 42] . Olomoucine has been used as a standard. The results are reported in Table 2 . The results from Table 2 reveal that compounds 1, 3, and 14-16 show very significant CDK2 inhibitory activity. Compound 3 was found to be as active as olomoucine, while compounds 1 and 14-16 were more potent than the standard compound. Once again the same structural features are present in active compounds as is evident in compounds active as anti-HIV-1.
Conclusions
According to the data obtained from the biological assay five compounds 5, 11, 14, 16, and 17 have shown very good anti-HIV activity in MT-2 cells. Similarly, five compounds (1, 3, and 14-16) have exhibited remarkable CDK2 inhibition activity. Compounds 14 and 16 can be considered as a significant matrix for the design and synthesis of novel candidates with dual anti-HIV and anticancer activities. Further investigation into the other aspects of structure activity relationship studies of this series of compounds is required in order to explore the scope and limitation of its biological activities.
